• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Treatment-emergent cefiderocol resistance in carbapenem-resistant is associated with insertion sequence IS in the siderophore receptor .碳青霉烯类耐药 中治疗期出现的头孢他啶耐药与铁载体受体中的插入序列 IS 有关。
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0029024. doi: 10.1128/aac.00290-24. Epub 2024 May 29.
2
Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam.舒巴坦-多利培南成功治疗耐碳青霉烯鲍曼不动杆菌脑膜炎
Clin Infect Dis. 2024 Oct 15;79(4):819-825. doi: 10.1093/cid/ciae210.
3
Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant spp.碳青霉烯类耐药 株中阿维巴坦和舒巴坦与头孢地尔的异性拮抗作用。
Microbiol Spectr. 2024 Oct 3;12(10):e0093024. doi: 10.1128/spectrum.00930-24. Epub 2024 Aug 20.
4
Efficacy of Cefiderocol, a Novel Siderophore Cephalosporin, against Multidrug Resistant Acinetobacter baumannii Clinical Isolates in Japan.新型铁载体头孢菌素头孢地尔对日本多药耐药鲍曼不动杆菌临床分离株的疗效
Jpn J Infect Dis. 2024 May 23;77(3):178-181. doi: 10.7883/yoken.JJID.2023.364. Epub 2024 Jan 31.
5
Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria.头孢地尔在与阿维巴坦、舒巴坦或他唑巴坦联合使用时对碳青霉烯类耐药革兰氏阴性菌的协同作用。
Cells. 2024 Aug 6;13(16):1315. doi: 10.3390/cells13161315.
6
In vitro activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii carrying various β-lactamase encoding genes.头孢地尔在体外对携带不同β-内酰胺酶编码基因的碳青霉烯类耐药鲍曼不动杆菌的活性。
Eur J Clin Microbiol Infect Dis. 2024 Jun;43(6):1171-1179. doi: 10.1007/s10096-024-04831-w. Epub 2024 Apr 23.
7
activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant collected in U.S. hospitals.美收集的对黏菌素耐药和/或头孢地尔罗非耐药、碳青霉烯类耐药的鲍曼不动杆菌的舒巴坦-多利培南活性。
Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0125823. doi: 10.1128/aac.01258-23. Epub 2024 Jan 30.
8
Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant Infections - A Systematic Review.舒巴坦-多利布坦，一种治疗多重耐药感染的新型药物 - 系统评价。
Infect Disord Drug Targets. 2024;24(6):e220124225835. doi: 10.2174/0118715265276432231217192054.
9
Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint.我们是否应该以及如何优化碳青霉烯类耐药鲍曼不动杆菌引起的严重医院获得性肺炎时的头孢地尔的给药方案？一种观点。
J Glob Antimicrob Resist. 2024 Sep;38:140-145. doi: 10.1016/j.jgar.2024.05.014. Epub 2024 Jun 5.
10
Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3.鲍曼不动杆菌中头孢地尔罗耐药性：β-内酰胺酶、铁载体受体和青霉素结合蛋白 3 的作用。
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01221-20.

引用本文的文献

1
Phenotypic and genotypic analysis of isolated from combat wounds in Ukraine during 2022 and 2023.2022年和2023年从乌克兰战斗伤口分离出的[具体物质未提及]的表型和基因型分析。
JAC Antimicrob Resist. 2025 Aug 7;7(4):dlaf140. doi: 10.1093/jacamr/dlaf140. eCollection 2025 Aug.
2
In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.新型抗菌剂对金属β-内酰胺酶产生菌的体外活性及耐药机制
Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1041-1068. doi: 10.1007/s10096-025-05080-1. Epub 2025 Mar 10.
3
Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.头孢地尔的活性、疗效及新出现的耐药机制研究进展
Curr Issues Mol Biol. 2024 Dec 14;46(12):14132-14153. doi: 10.3390/cimb46120846.
4
New Agents Are Coming, and So Is the Resistance.新的病原体正在出现，耐药性问题也随之而来。
Antibiotics (Basel). 2024 Jul 13;13(7):648. doi: 10.3390/antibiotics13070648.

本文引用的文献

1
Cefiderocol-containing regimens for the treatment of carbapenem-resistant ventilator-associated pneumonia: a propensity-weighted cohort study.含头孢地尔的方案治疗耐碳青霉烯类呼吸机相关性肺炎：一项倾向加权队列研究。
JAC Antimicrob Resist. 2023 Jul 20;5(4):dlad085. doi: 10.1093/jacamr/dlad085. eCollection 2023 Aug.
2
Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: A multicenter observational study.碳青霉烯类耐药鲍曼不动杆菌感染患者使用头孢地尔治疗的结局：一项多中心观察性研究。
J Infect Public Health. 2023 Sep;16(9):1485-1491. doi: 10.1016/j.jiph.2023.06.009. Epub 2023 Jun 14.
3
The clinical features and genomic epidemiology of carbapenem-resistant Acinetobacter baumannii infections at a tertiary hospital in Vietnam.越南一家三级医院耐碳青霉烯鲍曼不动杆菌感染的临床特征和基因组流行病学。
J Glob Antimicrob Resist. 2023 Jun;33:267-275. doi: 10.1016/j.jgar.2023.04.007. Epub 2023 Apr 27.
4
Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study.头孢地尔在实际临床环境中的疗效：单中心回顾性研究。
Antibiotics (Basel). 2023 Apr 13;12(4):746. doi: 10.3390/antibiotics12040746.
5
Cefiderocol Resistance in Klebsiella pneumoniae Is Linked to SHV Extended-Spectrum β-Lactamase Activities and Functional Loss of the Outer Membrane Porin OmpK35.肺炎克雷伯菌对头孢地尔的耐药性与其 SHV 型超广谱β-内酰胺酶活性和外膜孔蛋白 OmpK35 的功能丧失有关。
Microbiol Spectr. 2023 Jun 15;11(3):e0349622. doi: 10.1128/spectrum.03496-22. Epub 2023 Apr 25.
6
Mobile genetic elements in Acinetobacter antibiotic-resistance acquisition and dissemination.移动遗传元件在不动杆菌获得和传播抗生素耐药性中的作用。
Ann N Y Acad Sci. 2022 Dec;1518(1):166-182. doi: 10.1111/nyas.14918. Epub 2022 Oct 31.
7
Evolution and Transmission of Cefiderocol-Resistant Acinetobacter baumannii During an Outbreak in the Burn Intensive Care Unit.在烧伤重症监护病房暴发期间，对头孢地尔耐药鲍曼不动杆菌的进化和传播。
Clin Infect Dis. 2023 Feb 8;76(3):e1261-e1265. doi: 10.1093/cid/ciac647.
8
Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance.美国医院中的耐碳青霉烯类鲍曼不动杆菌：流行谱系的多样化与抗菌药物耐药性
mBio. 2022 Apr 26;13(2):e0275921. doi: 10.1128/mbio.02759-21. Epub 2022 Mar 21.
9
Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.头孢地尔罗与多粘菌素联合方案治疗碳青霉烯类耐药鲍曼不动杆菌引起的严重感染的比较。
Antimicrob Agents Chemother. 2022 May 17;66(5):e0214221. doi: 10.1128/aac.02142-21. Epub 2022 Mar 21.
10
Cefiderocol for Severe Carbapenem-Resistant Pneumonia: Towards the Comprehension of Its Place in Therapy.头孢地尔治疗重症碳青霉烯类耐药肺炎：对其在治疗中地位的理解
Antibiotics (Basel). 2021 Dec 21;11(1):3. doi: 10.3390/antibiotics11010003.

碳青霉烯类耐药 中治疗期出现的头孢他啶耐药与铁载体受体中的插入序列 IS 有关。

Treatment-emergent cefiderocol resistance in carbapenem-resistant is associated with insertion sequence IS in the siderophore receptor .

机构信息

Department of Environmental Health Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Department of Internal Medicine, Division of Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

出版信息

Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0029024. doi: 10.1128/aac.00290-24. Epub 2024 May 29.

DOI:10.1128/aac.00290-24
PMID:38809000
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11232405/
Abstract

We report the emergence of cefiderocol resistance in a carbapenem-resistant isolate from a sacral decubitus ulcer. Cefiderocol was initially used; however, a newly approved sulbactam-durlobactam therapy with source control and flap coverage was successful in treating the infection. Laboratory investigation revealed cefiderocol resistance mediated by IS insertion into the siderophore receptor .

摘要

我们报告了一例源于骶部褥疮的耐碳青霉烯肠杆菌科细菌分离株出现头孢他啶-阿维巴坦耐药。最初使用了头孢他啶-阿维巴坦，但通过来源控制和皮瓣覆盖的新批准的舒巴坦-多利巴坦治疗成功治愈了感染。实验室研究发现，通过插入铁载体受体的插入IS 介导的头孢他啶耐药。